ViAqua Therapeutics ⚠ Under review

About

Headcount over time

Offices

Q&A

What is ViAqua Therapeutics' primary focus?

ViAqua Therapeutics is an Israeli biotechnology company that develops orally administered RNA-particle platforms to improve animal health and prevent viral epidemics in aquaculture.

What is ViAqua Therapeutics' initial product designed to address?

ViAqua Therapeutics' initial product is an RNA-based solution targeting the White Spot Shrimp Virus (WSSV) pandemic, a significant challenge in the aquaculture industry.

When was ViAqua Therapeutics founded?

ViAqua Therapeutics was founded in 2014.

How much funding has ViAqua Therapeutics raised in total?

ViAqua Therapeutics has raised a total of $17.6 million USD.

When did ViAqua Therapeutics complete its A Round funding, and who was a lead investor?

In September 2023, ViAqua Therapeutics completed an A Round funding of $8.25 million USD, with.

When did ViAqua Therapeutics secure its Seed funding, and who was a lead investor?

In June 2021, ViAqua Therapeutics announced a Seed investment of $4.3 million USD, led by.

What is the current employee count range for ViAqua Therapeutics?

ViAqua Therapeutics has 11-50 employees.

Where is ViAqua Therapeutics headquartered?

ViAqua Therapeutics is headquartered in Haifa, Israel.

Team · 8

Shai Ufaz

Founder · CEO & Co-Founder

Shai Einbinder

Founder · Co-Founder

Limor Dori Alon

VP Business Development

Elad Zohar

VP Business Development

Ori Koshet

Operations Manager | Formulation

Rita Kanteev

Director of R&D | Chemistry

Chris Beattie

Active Director of ViAqua Therapeutics | Chief Scientific Officer for AquaBounty &"Champion of Innovation"

Prof. Avi Schroeder

Scientific Advisor | Drug delivery

Sectors & technology

Highlights

Tags